LYNCH DANIEL 4
4 · SpringWorks Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
LYNCH DANIEL
Director
Transactions
- Sale
Common Stock
2025-02-10$53.23/sh−69,766$3,713,553→ 236,178 total - Sale
Common Stock
2025-02-10$55.51/sh−65,600$3,641,751→ 130,944 total - Sale
Common Stock
2025-02-10$54.88/sh−39,634$2,175,047→ 196,544 total
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on May 3, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.00 to $53.80. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.28 to $55.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.40 to $55.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.